Thrivent Financial For Lutherans Blueprint Medicines Corp Transaction History

Thrivent Financial For Lutherans

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 14, 2023	SELL	$46.9 - $66.0 $425,758 - $599,148	-9,078 Reduced 62.21%	5,515 $277,000
Q2 2023 Aug 14, 2023	SELL	$42.2 - $66.37 $17,766 - $27,941	-421 Reduced 2.8%	14,593 $922,000
Q4 2022 Feb 08, 2023	BUY	$41.06 - $66.48 $431,910 - $699,303	10,519 Added 234.02%	15,014 $658,000
Q3 2022 Nov 14, 2022	BUY	$49.93 - $77.7 $224,435 - $349,261	4,495 New	4,495 $296,000
Q2 2022 Aug 16, 2022	SELL	$45.23 - $70.15 $522,180 - $809,881	-11,545 Closed	0 $0
Q1 2022 May 13, 2022	BUY	$54.1 - $110.08 $624,584 - $1.27 Million	11,545 New	11,545 $737,000
Q3 2020 Nov 10, 2020	SELL	$66.45 - $92.7 $392,254 - $547,208	-5,903 Closed	0 $0
Q1 2020 May 15, 2020	BUY	$48.11 - $82.22 $283,993 - $485,344	5,903 New	5,903 $345,000

351

60.3M

2.25M

1.18M

Ticker BPMC
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 59,719,600
Market Cap $5.4B
Description
Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibit...

Get notified when there are updates to the investment portfolio of Thrivent Financial For Lutherans, based on Form 13F filings with the SEC.

Stay updated on Thrivent Financial For Lutherans with notifications on news.